FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891818525> ?p ?o ?g. }

• W2891818525 abstract "Introduction Amyloid transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) is a progressive and fatal disease manifested by a build-up of TTR in the heart. ATTR-CM may be caused by mutations in TTR (hereditary ATTR [hATTR]) or deposition of normal TTR in older individuals (wild-type ATTR [wtATTR]). Natural history data show a progressive decline in cardiac functional and structural parameters specifically reduction in 6-minute walk test (6MWT) distance and increased left ventricular mass (LVM). Inotersen, an antisense oligonucleotide inhibitor of TTR production, has demonstrated safety and efficacy in the NEURO-TTR study involving patients with hATTR, including patients with extensive cardiac disease. We previously reported the efficacy and safety of inotersen in patients with hATTR-CM and wtATTR-CM after 1 year of treatment. Hypothesis Longer-term treatment with inotersen stabilizes and/or improves CM in patients with hATTR-CM and wtATTR-CM. Methods Patients with biopsy proven hATTR-CM or wtATTR-CM, interventricular septum [IVS] thickness ≥1.3 cm[A1] [A2] on echo, and evidence of congestive heart failure [CHF]) received 300 mg inotersen by subcutaneous injection weekly in a single center, open-label, investigator initiated study. Safety monitoring included complete blood count and assessment of renal function. Assessments included plasma TTR levels, 6MWT distance, and echo and cardiac MRI measurements of cardiac structure. Results As of January 2018, 15 of 25 patients enrolled in this study completed 2 years of inotersen treatment; 8 patients had hATTR-CM (mean age at entry, 63 years) and 7 patients had wtATTR-CM (mean age at entry, 74 years). Five patients completed 3 years of treatment (hATTR-CM, n=4; wtATTR-CM, n=1). Inotersen was well-tolerated. No drug-related serious adverse events (AEs) occurred and there were no severe thrombocytopenia or renal AEs. TTR suppression ranged from 42% to 93%; maximal mean TTR suppression was 77%. An additional 1-year of follow-up demonstrated continued improvement in 6MWT distances and reduction in LVM from previously reported results. Improvement from baseline in 6MWT distance was 41 meters at 2 years compared with 29 meters at 1 year. An 8.5% reduction in LVM was observed at 2 years compared with a 0.54% reduction observed at 1 year. Interventricular septal thickness decreased or remained stable in most patients and left ventricular ejection fraction increased or remained stable in most patients. Conclusions Long-term treatment with inotersen was well-tolerated and resulted in improvement or stabilization in cardiac function and structure in patients with hATTR-CM and wtATTR-CM. Sustained and substantially reduced serum TTR levels were demonstrated, depleting the substrate for amyloid production. Additionally, improvement in 6MWT distances and decreased LVM suggest possible improvement in cardiac function. [A1] [A2]" @default.
• W2891818525 created "2018-09-27" @default.
• W2891818525 creator A5043229467 @default.
• W2891818525 creator A5053804734 @default.
• W2891818525 date "2018-08-01" @default.
• W2891818525 modified "2023-09-26" @default.
• W2891818525 title "Long-term Treatment with Inotersen for Amyloid Transthyretin Amyloidosis Cardiomyopathy" @default.
• W2891818525 doi "https://doi.org/10.1016/j.cardfail.2018.07.263" @default.
• W2891818525 hasPublicationYear "2018" @default.
• W2891818525 type Work @default.
• W2891818525 sameAs 2891818525 @default.
• W2891818525 citedByCount "1" @default.
• W2891818525 countsByYear W28918185252021 @default.
• W2891818525 crossrefType "journal-article" @default.
• W2891818525 hasAuthorship W2891818525A5043229467 @default.
• W2891818525 hasAuthorship W2891818525A5053804734 @default.
• W2891818525 hasConcept C121157162 @default.
• W2891818525 hasConcept C126322002 @default.
• W2891818525 hasConcept C142724271 @default.
• W2891818525 hasConcept C164705383 @default.
• W2891818525 hasConcept C2777607188 @default.
• W2891818525 hasConcept C2777633098 @default.
• W2891818525 hasConcept C2778198053 @default.
• W2891818525 hasConcept C2778797674 @default.
• W2891818525 hasConcept C2778921608 @default.
• W2891818525 hasConcept C2779740085 @default.
• W2891818525 hasConcept C2779951007 @default.
• W2891818525 hasConcept C71924100 @default.
• W2891818525 hasConceptScore W2891818525C121157162 @default.
• W2891818525 hasConceptScore W2891818525C126322002 @default.
• W2891818525 hasConceptScore W2891818525C142724271 @default.
• W2891818525 hasConceptScore W2891818525C164705383 @default.
• W2891818525 hasConceptScore W2891818525C2777607188 @default.
• W2891818525 hasConceptScore W2891818525C2777633098 @default.
• W2891818525 hasConceptScore W2891818525C2778198053 @default.
• W2891818525 hasConceptScore W2891818525C2778797674 @default.
• W2891818525 hasConceptScore W2891818525C2778921608 @default.
• W2891818525 hasConceptScore W2891818525C2779740085 @default.
• W2891818525 hasConceptScore W2891818525C2779951007 @default.
• W2891818525 hasConceptScore W2891818525C71924100 @default.
• W2891818525 hasLocation W28918185251 @default.
• W2891818525 hasOpenAccess W2891818525 @default.
• W2891818525 hasPrimaryLocation W28918185251 @default.
• W2891818525 hasRelatedWork W1975067812 @default.
• W2891818525 hasRelatedWork W1991252968 @default.
• W2891818525 hasRelatedWork W2007183235 @default.
• W2891818525 hasRelatedWork W2059978718 @default.
• W2891818525 hasRelatedWork W2062804491 @default.
• W2891818525 hasRelatedWork W2232564982 @default.
• W2891818525 hasRelatedWork W2416206776 @default.
• W2891818525 hasRelatedWork W2546484415 @default.
• W2891818525 hasRelatedWork W2580160290 @default.
• W2891818525 hasRelatedWork W2765942577 @default.
• W2891818525 hasRelatedWork W2883355034 @default.
• W2891818525 hasRelatedWork W2999710862 @default.
• W2891818525 hasRelatedWork W3003269031 @default.
• W2891818525 hasRelatedWork W3009738017 @default.
• W2891818525 hasRelatedWork W3046143986 @default.
• W2891818525 hasRelatedWork W3106641441 @default.
• W2891818525 hasRelatedWork W3120677967 @default.
• W2891818525 hasRelatedWork W3135950685 @default.
• W2891818525 hasRelatedWork W3186668188 @default.
• W2891818525 hasRelatedWork W3210326233 @default.
• W2891818525 isParatext "false" @default.
• W2891818525 isRetracted "false" @default.
• W2891818525 magId "2891818525" @default.
• W2891818525 workType "article" @default.